Determination of apoptotic effects of newly synthesized avobenzone Sm(III) complex in non-small cell lung cancer

Abstract

In this study, we aimed to investigate the apoptotic effects of the lanthanide complex TBK-23, which was used in biological imaging due to its magnetic and spectroscopic properties. The study utilized HTB-54 and BEAS-2B cell lines. The cells were subjected to TBK-23 and cisplatin at active doses for a duration of 24 hours. Subsequently, flow cytometry was employed to assess the quantity of apoptotic cells, while quantitative RT-PCR was used to measure the expression levels of BAX, BCL-2, and BCL-xL. While cisplatin at 31 µM increased the proapoptotic BAX expression level in HTB-54 and BEAS-2B cells, TBK-23 increased BAX in cancer cells at the same concentration, but there was no observable effect in healthy cells. TBK-23 was found to have higher inhibitory effect on the expression of the antiapoptotic BCL-2 gene in cancer cells compared to that of cisplatin-treated cells. Consequently, it was determined that TBK-23, a novel metal-based compound, exhibited apoptotic effects similar to that of cisplatin and could be a potential chemotherapeutic agent.

Keywords

• Lung Cancer
• Apoptosis
• Chemotherapy
• Lanthanide Complex

Supporting Institution

Gaziantep Üniversity

Thanks

Respiratory Diseases and Respiratory Surgery Research and Practice Center, Gaziantep University

References

1. 1World Cancer Research Fund International Home Page. https://www.wcrf.org/cancer-trends/lung-cancer-statistics. (accessed 23 March 2022)
2. Xia, L.; Tan, S.; Zhou, Y.; Lin, J.; Wang, H.; Oyang, L.; Tian, Y.; Liu, L.; Su, M.; Wang, H.; Cao, D.; Liao, Q. Onco Targets Ther. 2018, 11, 2063-73.
3. Lengauer, C.; Kinzler, K.W.; Vogelstein, B. Nature. 1998, 396, 643–649.
4. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, RL.; Torre, L.A.; Jemal, A. CA Cancer J. Clin. 2018, 68, 394–424.
5. Elbe, E.; Yigitturk, G.; Cavusoglu, T.; Uyanikgil, Y. Bratislava Medical Journal. 2020, 121, 122–128.
6. Chen, C.C.; Kao, C.P.; Chiu, M.M.; Wang, S.H. Oncotarget. 2017, 8(65), 109340–109357.
7. Zhang, C., : Xu, C.,; Gao, X.,; Yao Q. Theranostics. 2022, 12(5), 2115–2132.
8. Makovec, T. Radiol Oncol. 2019, 28;53(2),148-158

9. Tăbăcaru, A.; Botezatu Dediu, A.V.; Mihaela, D.R.; Cârâc, G.; Basliu, V.; Paula, Cabral C. M.; Silva, Francisco.; Pinto, C.I.G.; Guerreiro, F.; Martins, M.; Mendes, F.; Marques, F. Inorganica Chim Acta. 2020, 506, 119517.
10. Chundawat, N.S.; Jadoun, S.; Zarrintaj, P.; Chauhan, N.P.S. Polyhedron. 2021, 207, 115387.
11. Sarıoğlu, A.O.; Kahraman, D.T.; Köse, A.; Sönmez, M. J. Mol Struct. 2022, 1260, 132786.
12. Zappa, C.; Mousa, S.A. Trans. Lung Cancer Res. 2016, 5, 288–300.
13. Le ,X.; Hanna, E.Y. Ann Trans. Med. 2018, 6, 229–229.
14. Chundawat, N.; Jadoun, S.; Zarrintaj P.; Chauhan, N. Polyhedron. 2021, 207, 115387.
15. Cory, S.; Adams, J.M. Nat. Reviews Cancer. 2002, 9, 647–656.
16. Jeong, S.H.; Lee, H.W.; Han, J.H.; Kang, S.Y.; Choi, J.H.; Jung, Y.M. Jpn J Clin Oncol. 2008, 10, 661–669.